Study on the Effectiveness and Safety of Octreotide Subcutaneous Depot in Patients with Advanced GEP-NET

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of advanced, well-differentiated neuroendocrine tumors (NET) of the gastroenteropancreatic (GEP) system or presumed GEP origin.
• Have at least one measurable tumor that shows up on specific scans and tests.
• Be in relatively good health, with an ECOG performance status score between 0 and 2, meaning fully active or restricted in physically strenuous activity but ambulatory.

Exclusion Criteria

• Have evidence of disease progression while on treatment for advanced or metastatic disease.
• Have known cancer spread to the brain or central nervous system.
• Have been on long-acting somatostatin analogs (SSAs) for more than 6 months before joining the study.
• Have carcinoid symptoms that do not respond to standard doses of octreotide LAR or lanreotide ATG, or to daily doses of octreotide IR.
• Have had more than one cycle of certain targeted therapies, chemotherapy, or interferon for GEP-NET.
• Have had specific treatments like trans-arterial chemoembolization or embolization within 12 months before joining the study.
• Have received radioligand therapy (PRRT) at any time.